The US Food and Drug Administration will now require GLP-1 drugs including Novo's Wegovy and Ozempic and Lilly's Mounjaro, Zepbound and Foundayo to carry warnings that they may increase the risk of non-arteritic anterior ischemic optic neuropathy, or NAION. Novo will continue to review new research and monitor the safety of its medicines, said Liz Skrbkova, director of media and stakeholder relations, in a statement.